Fig. 5: SREBP2 facilitates mtDNA damage by augmenting PCSK9 expression in vitro.

A mtDNA damage measurement in control and Ang II-induced HL-1 cells. B mtROS production measurement in control and Ang II-induced HL-1 cells. C RT-qPCR detection of PCSK9 expression in atrial tissues of normal and Ang II-treated mice. D RT-qPCR detection of PCSK9 expression in control and Ang II-induced HL-1 cells. E RT-qPCR detection of PCSK9 expression in HL-1 cells treated with oe-SREBP2. F RT-qPCR detection of SREBP2 expression in HL-1 cells treated with sh-SREBP2-1 or sh-SREBP2-2. G RT-qPCR detection of PCSK9 expression in HL-1 cells treated with oe-PCSK9. H RT-qPCR detection of SREBP2 and PCSK9 expression in HL-1 cells treated with sh-SREBP2 or combined with oe-PCSK9. I mtDNA damage measurement in HL-1 cells treated with sh-SREBP2 or combined with oe-PCSK9. J mtROS production measurement in HL-1 cells treated with sh-SREBP2 or combined with oe-PCSK9. *p < 0.05, compared with the normal mice, control HL-1 cells, Ang II-induced HL-1 cells treated with sh-NC, oe-NC or sh-NC + oe-NC. # p < 0.05, compared with the Ang II-induced HL-1 cells treated with sh-SREBP2 + oe-NC. All experiments were repeated three times independently. n = 10 for mice in each group.